Claims
- 1. A method of treating pulmonary inflammation in a mammal in need thereof, which comprises administering to said mammal an antiinflammatory effective amount of a compound of the structure ##STR15## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen, --CONR.sup.3 (CR.sup.4 R.sup.5).sub.m (CR.sup.6 R.sup.7).sub.n (CR.sup.8 R.sup.9).sub.p NR.sup.10 R.sup.11, ##STR16## or CONR.sup.3 R.sup.13 ; R.sup.3 is hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl of 4-10 carbon atoms;
- R.sup.4, R.sup.5, R.sup.8, and R.sup.9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, --OH, --CF.sub.3, or --F;
- R.sup.6 is hydrogen or --OR.sup.14 ;
- R.sup.7 is hydrogen or alkyl of 1-6 carbon atoms;
- R.sup.10 is hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl of 4-10 carbon atoms;
- R.sup.11, R.sup.12, and R.sup.13 are each, independently, --(CR.sup.15 R.sup.16).sub.r R.sup.17 ;
- R.sup.14 is hydrogen, alkyl of 1-6 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, or tetrahydropyranyl;
- R.sup.15 and R.sup.16 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; ##STR17## or --C.ident.C--R.sup.21 ; R.sup.18, R.sup.19, R.sup.20, and R.sup.21 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, halogen, or phenyl, wherein the phenyl group may be optionally mono-, di-, or tri-substituted with a group selected from alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoroalkoxy of 1-6 carbon atoms, cyano, halo, hydroxy, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, dialkylamino of 1-6 carbon atoms per alkyl group, dialkylaminoalkyl of 3-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkylthio of 1-6 carbon atoms, --SO.sub.3 H, --PO.sub.3 H, and --CO.sub.2 H; ##STR18## is a 5-7 membered saturated or partially unsaturated heterocyclic radical containing at least 2 ring nitrogens, wherein the heterocyclic ring may optionally contain NR.sup.22 in the heterocyclic ring, and the ring carbons may optionally be substituted by alkyl of 1-6 carbon atoms, arylalkyl of 4-10 carbon atoms, halogen, --CF.sub.3, --OR.sup.14, or --CO.sub.2 R.sup.10 ;
- R.sup.22 is hydrogen, alkyl of 1-6 carbon atoms, or arylalkyl of 4-10 carbon atoms;
- m=0-6;
- n=1-6;
- p=0-6; and
- r=1-6
- with the proviso that R.sup.1 and R.sup.2 are both not hydrogen, or a pharmaceutically acceptable salt thereof.
Parent Case Info
This is a division of application Ser. No. 08/284,764, filed Aug. 2, 1994 abandoned, which is a continuation-in-part of Ser. No. 08/160,984, filed Dec. 1, 1993, abandoned which is a divisional of Ser. No. 08/054,655, filed Apr. 23, 1993 (now U.S. Pat. No. 5,302,584), which is a continuation-in-part of Ser. No. 07/960,597, filed Oct. 13, 1992 abandoned.
US Referenced Citations (33)
Foreign Referenced Citations (2)
Number |
Date |
Country |
507555A1 |
Jul 1992 |
EPX |
WO9113899 |
Sep 1991 |
WOX |
Non-Patent Literature Citations (11)
Entry |
Venzina, C., J. Antibiot. 28:721 (1975). |
Sehgal, S. N., J. Antibiot. 28:727 (1975). |
Baker, H. J., Antibiot. 31:539 (1978). |
Martel, R. R., Can. J. Physiol. Pharmacol. 55:48 (1977). |
Staruch, M. J., FASEB 3:3411 (1989). |
Dumont, F. J., FASEB 3:5256 (1989). |
Calne, R. Y., Lancet 1183 (1978). |
Morris, R. E., Med. Sci. Res. 17:877 (1989). |
Baeder, W. L., Fifth Int. Conf. Inflamm. Res. Assoc. 121 (Abstract)(1990). |
Meiser, B. M., J. Heart Lung Transplant. 11 (pt. 2):197 (1992). |
Stepkowski, S. M., Transplantation Proc. 23:507 (1991). |
Divisions (2)
|
Number |
Date |
Country |
Parent |
284764 |
Aug 1994 |
|
Parent |
54655 |
Apr 1993 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
160984 |
Dec 1993 |
|
Parent |
960597 |
Oct 1992 |
|